The robots aren't coming. They're already here.
When done right, pairing quality and value can be an especially potent investing strategy. Medtronic's revenue edged higher as currency-neutral non-GAAP EPS dipped a bit in the fiscal fourth quarter. Relative to its size, the company's $17 billion in net debt is quite manageable.
Novo Nordisk and Medtronic are longtime leaders in the healthcare industry. Both are proven innovators with attractive prospects in the years ahead.
MDT stock enjoys a bullish rating from analysts and Seeking Alpha writers. But insider transactions are completely dominated by selling - for good reasons in my view. The valuation is not as attractive as on the surface once growth is factored in.
Medtronic plc (NYSE:MDT ) Goldman Sachs 45th Annual Global Healthcare Conference Call June 11, 2024 10:40 AM ET Company Participants Geoff Martha - Chairman & Chief Executive Officer Conference Call Participants David Roman - Goldman Sachs David Roman Good morning, everybody. I want to welcome everyone here to the 45th Annual Global Healthcare Conference.
For Hugo surgical robot, Medtronic (MDT) is scaling manufacturing production, expanding regulatory approvals and ramping up installations to see continued progress internationally.
Medtronic has been increasing its dividend for decades. But the rate of its increases has slowed drastically in recent years.
Medtronic's (NYSE: MDT) diabetes segment, which sells insulin pumps, continuous glucose monitoring systems, and consumables has seen its revenue rise at a slower pace of 1.4% annually from $2.4 billion in fiscal 2020 (fiscal ends in April) to $2.5 billion in fiscal 2024. The slower growth can be attributed to unfavorable currency translation, given that over 60% of the segment sales are derived from markets outside the U.S. However, we think the company will see a pickup in diabetes sales going forward.
Dividend stocks are the best way to play a market potentially on the cusp of a massive rebound, thanks to the Federal Reserve potentially cutting rates three times if inflation stays low, which has made the market more optimistic. The latest Bureau of Economic Analysis report shows that inflation cooled slightly in April.
Medtronic and Altria are two value stocks with long track records of raising dividends for over 25 consecutive years. Medtronic is a healthcare technology company with strong revenue growth and a safe dividend yield of 3.4%. Altria, despite challenges in the tobacco industry, offers an 8.5% dividend yield and potential upside from its e-vapor business and strategic investments.
Medtronic's growth rate has been showing signs of improvement. The company recently announced it would be raising its dividend for the 47th consecutive year.
Medtronic exceeded quarterly forecasts last week, but its stock got punished anyway. Shares cost nearly 30x earnings, but those earnings are growing painfully slowly.